[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:penile-squamous-cell-carcinoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":28,"states":29},"Penile Squamous Cell Carcinoma",3,[7,15,22],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06104618","Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis",[11],"Phase 2","RECRUITING","2026-08-26T02:17:30.145302Z","2026-05-05T02:43:28.177900Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT05639972","E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers",[19],"Phase 1\u002FPhase 2","2026-08-26T02:17:33.002248Z","2026-07-05T05:32:16.809101Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT06161532","Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder\u002FUrinary Tract Cancer, Renal Medullary Carcinoma and Penile C...",[11],"2026-08-26T02:16:46.147215Z","2026-05-05T02:43:28.172497Z",[],[]]